孟鲁司特钠联合奥洛他定治疗慢性荨麻疹对患者免疫功能及相关炎性因子的影响  

Influences of the combination treatment of montelukast sodium and olotadine on the immune function and inflammatory factors in patients with chronic urticaria

作　　者：杨帆[1] YANG Fan(Department of Dermatology and venereology,the People’s Hospital of Langfang City,Hebei,Langfang 065000,China)

机构地区：[1]河北省廊坊市人民医院皮肤性病科,065000

出　　处：《河北医药》2023年第13期1972-1975,共4页Hebei Medical Journal

基　　金：廊坊市科学技术研究与发展计划(编号:2020013070)。

摘　　要：目的观察孟鲁司特钠联合奥洛他定治疗慢性荨麻疹对患者免疫功能及相关炎性因子的影响。方法选择2019年8月至2020年8月收治的慢性荨麻疹患者156例,随机数字表法分为观察组和对照组,每组78例。观察组采用孟鲁司特钠联合联合奥洛他定治疗,对照组采用奥洛他定治疗。比较2组疗效,血清炎性因子(hs-CRP、TNF-α、IL-6、组胺、LT)、Th1/Th2细胞因子、免疫相关指标(T淋巴细胞亚群、补体C3、C4血清总IgE)、生活质量。结果治疗组总有效率为88.46%高于对照组的76.92%(P<0.05)。治疗后,2组血清炎性相关因子hs-CRP、TNF-α、IL-6、嗜酸性粒细胞比例、组胺及LT水平均较治疗前显著降低(P<0.05),且观察组均显著低于对照组(P<0.05)。治疗后,2组血清IL-4水平均较治疗前显著下降(P<0.05),IFN-γ水平显著升高(P<0.05),且观察组上述两项指标较对照组变化更明显(P<0.05)。治疗后,2组血清C3、C4、CD4^(+)、CD4^(+)/CD8^(+)水平均较治疗前升高(P<0.05),且观察组高于对照组(P<0.05),CD8^(+)及总IgE水平均较治疗前降低(P<0.05),且观察组低于对照组(P<0.05)。治疗后,2组CU-Q2oL评分均较治疗前降低(P<0.05),且观察组低于对照组(P<0.05)。结论孟鲁司特钠联合联合奥洛他定治疗慢性荨麻疹能改善患者免疫功能,降低相关炎性因子水平,提高患者生活质量。Objective To observe the influences of the combination treatment of montelukast sodium andolotadineon the immune function and inflammatory factors in patients with chronic urticaria.Methods A total of 156 patients with chronic urticaria treated from August 2019 to August 2020 were randomly divided into observation group(n=78)and control group(n=78).Olotadine was given to all patients,and montelukast sodium was additionally given to patients of observation group.Therapeutic efficacy,serum levels of inflammatory factors including high-sensitivity C-reactive protein(hs-CRP),C-reactive protein(CRP),interleukin-6(IL-6),tumour necrosis factor-α(TNF-α),histamine,leukotriene(LT),Th1/Th2 cytokines,immune-related indicators including T lymphocyte subsets,complement C3,C4,serum total immunoglobulin E(IgE)and quality of life were compared between groups.Results After treatment,the total effective rate in the observation group was significantly higher than that in the control group(88.46%vs 76.92%,P<0.05).The serum levels ofhs-CRP,TNF-α,and IL-6,eosinophil ratio,histamine and LT levels significantly decreased compared with those before treatment(all P<0.05),which were significantly lower in the observation group than incontrol group(all P<0.05).The serum IL-4 level in both groups significantly decreased,and serum interferon-gamma(IFN-γ)level significantly increased,which were more pronounced in the observation group(all P<0.05).The serum levelsof C3,C4,CD4^(+)and CD4^(+)/CD8^(+)in bothgroups significantly increased,while the levels of CD8^(+)and total IgEsignificantlydecreased,which were more pronounced in the observation group(all P<0.05).The Chronic Urticaria Quality of Life(CU-QoL)scores in both groups were lower than before treatment(P<0.05),which were significantly lower in the observation group than those in the control group(P<0.05).Conclusion Montelukast sodium combined with olodadine in the treatment of chronic urticaria can improve the immune function and quality of life,and reduce the levels of inflammatory fac

关 键 词：慢性荨麻疹 孟鲁司特钠 奥洛他定 炎症 免疫 

分 类 号：R758.24[医药卫生—皮肤病学与性病学]